CLAIMS:

1. A composition for use in preventing and/or treating anaemia comprising an iron hydroxypyrone for administration to a subject, wherein the gastric pH of the subject is equal to or greater than about 4.

2. The composition of Claim 1, wherein the gastric pH of the subject is greater than 5 or 6, for example about 6.5 or above or wherein the subject has or is at risk of having achlorhydria.

3. The composition according to Claim 1 or Claim 2, wherein the subject has been, will be, or is being administered an acid reducing regimen or one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract.

4. The composition according to Claim 3, wherein the acid reducing regimen comprises an acid reducing agent and the acid reducing agent is selected from a proton pump inhibitor, an H_2 receptor antagonist, a substance capable of neutralising acids, or a combination thereof, or wherein the acid reducing agent is selected from omeprazole, lansoprazole, pantoprazole, ranitidine, famotidine, nizatidine, cimetidine, aluminium hydroxide, magnesium carbonate, sodium or potassium bicarbonate, or calcium carbonate, or a combination thereof or wherein the one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract which preferably requires a stomach acid reducing treatment regimen comprises a cobalt compound.

5. The composition according to Claim 4, wherein the cobalt compound comprises a cobalt salt or a cobalt complex or wherein the cobalt compound comprises cobalt (II) gluconate or cobalt (II) chloride, or a combination thereof.

6. The composition according to Claim 1 or Claim 2, further comprising one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract or an acid reducing regimen.

7. The composition of any one of Claims 1 to 6, wherein the anaemia is iron deficiency anaemia, and, optionally, the anaemia is associated with the inflammatory disease of the gastrointestinal tract.

8. The composition according to Claim 2, wherein the achlorhydria is associated with the inflammatory disease of the gastrointestinal tract.

9. The composition according to Claim 2 , wherein the achlorhydria is associated with atrophic gastritis or a gastrointestinal infection, such as caused by *Helicobacter pylori*.

10. The composition according to any one of Claims 1 to 9, wherein the iron hydroxyprone is a ferric complex with hydroxypyrone and the ferric complex is a 1:3 molar complex of iron to the hydroxypyrone, such as ferric trimaltol, or the iron hydroxypyrone is in the form of a solid, a liquid or a suspension in a liquid and comprises a mixture of a ferrous or a ferric salt and a hydroxypyrone.

11. The composition according to any one of Claims 1 to 10, wherein the iron hydroxypyrone is administered at the same time, before or after one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract, or the acid reducing regimen, preferably the iron hydroxypyrone is administered at the same time or subsequent to the one or more compounds or the acid reducing regimen.

12. The composition according to any one of Claims 1 to 11, wherein the composition is administered by oral administration.

13. The composition according to any one of Claims 1 to 12, wherein the composition is for the absorption of iron.

14. The composition according to any one of Claims 1 to 13 wherein the subject is a mammal such as a human.

15. A composition for use in preventing and/or treating anaemia comprising an iron hydroxypyrone for administration to a subject, wherein the subject has an inflammatory disease of the gastrointestinal tract or has achlorhydria, wherein the subject has been, will be, or is being administered an acid reducing regimen or one or more compounds capable

of treating and/or preventing an inflammatory disease of the gastrointestinal tract and wherein the acid reducing regimen comprises an acid reducing agent and the acid reducing agent is selected from a proton pump inhibitor, an H_2 receptor antagonist, a substance capable of neutralising acids, or a combination thereof, or wherein the acid reducing agent is selected from omeprazole, lansoprazole, pantoprazole, ranitidine, famotidine, nizatidine, cimetidine, aluminium hydroxide, magnesium carbonate, sodium or potassium bicarbonate, or calcium carbonate, or a combination thereof, or wherein the one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract which preferably requires a stomach acid reducing treatment regimen comprises a cobalt compound.

16. A composition for use in preventing and/or treating anaemia comprising an iron hydroxypyrone for administration to a subject, wherein the subject has achlorhydria and wherein the achlorhydria is associated with an inflammatory disease of the gastrointestinal tract or the achlorhydria is associated with atrophic gastritis or a gastrointestinal infection.

17. Use of an iron hydroxypyrone in the manufacture of a medicament for preventing and/or treating anaemia, such as iron deficiency anaemia, wherein the composition is for administration to a subject, wherein the gastric pH of the subject is equal to or greater than about 4.

CLAIMS:

1. A composition for use in preventing and/or treating anaemia comprising an iron hydroxypyrone for administration to a subject, wherein the subject has an inflammatory disease of the gastrointestinal tract or has achlorhydria.

2. The composition of Claim 1, wherein the gastric pH of the subject is equal to or greater than about 4, such as greater than 5 or 6, for example about 6.5 or above or wherein the subject has or is at risk of having achlorhydria.

3. The composition according to Claim 1 or Claim 2, wherein the subject has been, will be, or is being administered an acid reducing regimen or one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract.

4. The composition according to Claim 3, wherein the acid reducing regimen comprises an acid reducing agent and the acid reducing agent is selected from a proton pump inhibitor, an H_2 receptor antagonist, a substance capable of neutralising acids, or a combination thereof, or wherein the acid reducing agent is selected from omeprazole, lansoprazole, pantoprazole, ranitidine, famotidine, nizatidine, cimetidine, aluminium hydroxide, magnesium carbonate, sodium or potassium bicarbonate, or calcium carbonate, or a combination thereof or wherein the one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract which preferably requires a stomach acid reducing treatment regimen comprises a cobalt compound.

5. The composition according to Claim 4, wherein the cobalt compound comprises a cobalt salt or a cobalt complex or wherein the cobalt compound comprises cobalt (II) gluconate or cobalt (II) chloride, or a combination thereof.

6. The composition according to Claim 1 or Claim 2, further comprising one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract or an acid reducing regimen.

7. The composition of any one of Claims 1 to 6, wherein the anaemia is iron deficiency anaemia, and, optionally, the anaemia is associated with the inflammatory disease of the gastrointestinal tract.

8. The composition according to Claim 1 or Claim 2, wherein the achlorhydria is associated with the inflammatory disease of the gastrointestinal tract.

9. The composition according to Claim 1 or Claim 2 , wherein the achlorhydria is associated with atrophic gastritis or a gastrointestinal infection, such as caused by *Helicobacter pylori*.

10. The composition according to any one of Claims 1 to 9, wherein the iron hydroxyprone is a ferric complex with hydroxypyrone and the ferric complex is a 1:3 molar complex of iron to the hydroxypyrone, such as ferric trimaltol, or the iron hydroxypyrone is in the form of a solid, a liquid or a suspension in a liquid and comprises a mixture of a ferrous or a ferric salt and a hydroxypyrone.

11. The composition according to any one of Claims 1 to 10, wherein the iron hydroxypyrone is administered at the same time, before or after one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract, or the acid reducing regimen, preferably the iron hydroxypyrone is administered at the same time or subsequent to the one or more compounds or the acid reducing regimen.

12. The composition according to any one of Claims 1 to 11, wherein the composition is administered by oral administration.

13. The composition according to any one of Claims 1 to 12, wherein the composition is for the absorption of iron.

14. The composition according to any one of Claims 1 to 13 wherein the subject is a mammal such as a human.

15. Use of an iron hydroxypyrone in the manufacture of a medicament for preventing and/or treating anaemia, such as iron deficiency anaemia, wherein the composition is for

administration to a subject, wherein the subject has an inflammatory disease of the gastrointestinal tract or has achlorhydria.